Core Viewpoint - The company, Yipai Yangguang (02522), announced that its directors purchased a total of 96,500 H-shares in the open market, reflecting their confidence in the company's recent developments in medical imaging and AI applications [1] Group 1: Director Purchases - The chairman and CEO, Mr. Chen Chaoyang, along with other executive directors, purchased a total of 96,500 H-shares on November 3 and 4, 2025 [1] - The directors believe that the current H-share price does not fully reflect the company's long-term investment value [1] Group 2: Business Development - The directors' decision to increase their holdings is based on the company's recent achievements in regional medical imaging sharing centers and data services [1] - The company's strategic alignment with the State Council's implementation opinions on promoting AI in healthcare, issued on November 4, 2025, enhances their confidence in future growth [1] Group 3: Market Position - The company maintains sufficient public float in compliance with the Hong Kong Stock Exchange's listing rules, even after the recent share purchases [1]
一脉阳光(02522)：若干董事增持总计9.65万股H股